technology
technology
The colour of pain
Australian scientists have discovered a way to see pain and judge its severity.
Mark Hutchinson interviewed by Dallas Bastian
A new blood test that looks at the colour of a patient’ s pain will be able to notify health professionals of the pain’ s severity within minutes.
The on-the-spot test is able to identify chronic pain by looking at colour biomarkers in the blood.
The University of Adelaide’ s Professor Mark Hutchinson, who developed the test with an Australian-based team, said they found that persistent chronic pain has a different natural colour in immune cells than cases where there isn’ t persistent pain.“ We are literally quantifying the colour of pain,” he explained.
Hutchinson said the new tool, called the painHS test, not only allows for greater certainty of diagnosis but can also guide better drug treatment options.“ This gives us a brand new window into patients’ pain,” he added.
The neuroscientist told an Australian and New Zealand College of Anaesthetists meeting that the test would also benefit the diagnosis of pain in people with dementia who are unable to communicate the extent or source of their pain.
The test uses light measurement tools( hyperspectral imaging analysis) to identify the molecular structures of what pain looks like in blood cells. But Hutchinson stressed that the test could never replace the importance of having patients describe and discuss their pain.
“ Self-reporting is still going to be key, but what this does mean is that those‘ forgotten people’ who are unable to communicate their pain conditions – such as babies or people with dementia – can now have their condition diagnosed and treated,” he said.
Hutchinson added that the test will not only have a profound impact on human health but also has the potential to revolutionise the treatment of animals.“ Animals can’ t tell us if they’ re in pain, but here we have a Dr Doolittle-type test that enables us to‘ talk’ to the animals so we can find out if they are experiencing pain and then we can help them.” Nursing Review spoke with Hutchinson to find out more.
NR: Can you walk us through how the test works? MH: Sure. About 15 years ago, we made the beginnings of a discovery – which we finally worked out was a real discovery about five years ago – that we could use a patient’ s blood in a dish to give us a response out of that blood that was able to determine whether that person had pain or not. And persistent pain specifically. This is pain that’ s lasting more than three months.
The exciting thing was, that was the first time that we could objectively diagnose persistent pain. But the disappointing thing was that test was really expensive and it took several days to resolve the answer.
So over the past four years, at the ARC Centre of Excellence for Nanoscale BioPhotonics, we’ ve been working with physicists and chemists to understand whether we can take that many-day test and condense it down into something that lasts for about a few minutes. And what we’ re doing is using the natural colour of biology as a measure for what’ s happening in those cells in the blood.
So all biology has a colour. When we shine light through our finger and we see that red glow, that’ s the haemoglobin oxygenation that we’ re able to see. But if we use different types of lasers onto different types of cells and illuminate it with different colours, we get many rainbows of colours back towards us that we can then integrate together. And in this massive amount of information are the previously unrealised secrets of diagnosis of many disease states. And the one that we’ ve chosen is pain.
What setting do you see this test used in and for what types of pain would it be most useful? There are several areas where this test can be used. Pain is currently measured subjectively. We require someone to say how much pain they are in and to describe the type of pain they have.
Now that is assuming communication is an option. Children who have yet to gain verbal communication are unable to communicate their pain effectively. So, in children, this test would be critical in identifying chronic pain conditions, which are surprisingly common.
We also have the other end of the life spectrum, in the aged population, where dementia and other forms of delirium stop patients in their elderly years being able to communicate or acknowledge that they have a chronic pain. Again, this would be a test that would allow us to intervene with an objective measure.
The final one is actually at the very beginning of drug development. One of the biggest problems in targeting drugs to the brain and spinal cord is the failure rate of drugs in development from translating from the experimental setting into the clinic. And one of the huge hurdles is, we don’ t have an objective way to recruit the right patients – pain patients – into trials, nor do we have a tool to be able to say, yes, this drug actually worked, without again asking the patient.
So this kind of tool will be very important for future drug trials to be able to refine patient populations so we have a good chance of a drug succeeding, determining if it really does work and objectively measuring how well the drug works in the trial.
When are we likely to see the test used in Australia in health care settings? We are really keen to run large scale clinical trials in the next 18 months. These trials will mean that we will need to do multisensor, multi-site trials. And from there, we should be able to then seek the appropriate registration approaches. So it’ s going to be a bit of a longer journey. We still need to get the registration approved. But from there, we should be able to see it in patients’ hands.
Is this something you could see used widely in Australia? I think it will be used widely. We will be looking at the deployability down to the individual doctor’ s surgery, for example, where we really want this test used. So that means it won’ t be in everybody’ s home, I don’ t think, because of the cost associated with the read out, but it should be available very broadly.
And while we’ re talking about human health here, I think the bigger volume use will actually be in the animal sector, in the veterinary sector, where we literally cannot talk to the animals yet to work out whether they’ re in pain. So I think we’ ll see the veterinary use expand very quickly. ■
28 | nursingreview. com. au